Monitoring therapy effectiveness (glaucoma) through miniaturized, autonomous in-vivo sensing and data uploading to cloud database.
Injectsense has raised $2.5M in total funding. The most recent round was Convertible Note. The last funding was announced in November 2023.
Injectsense's investors include Leerink Revelation Partners, National Eye Institute.
Injectsense is headquartered in Emeryville, United States.
Monitoring therapy effectiveness (glaucoma) through miniaturized, autonomous in-vivo sensing and data uploading to cloud database.
Injectsense is at the Convertible Note stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Injectsense — Funding & Investors." VCBacked, November 15, 2023, https://www.vcbacked.co/company/injectsense. Accessed September 30, 2026.
VCBacked. (2023). Injectsense — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/injectsense
{{cite web |title=Injectsense — Funding & Investors |url=https://www.vcbacked.co/company/injectsense |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated